Pharmaceutical - Johnson & Johnson


Current filters:

Johnson & Johnson

Popular Filters

101 to 125 of 254 results

Setback for Janssen and Bayer's Xarelto as FDA calls for more info in stent thrombosis setting for ACS patients


Janssen Research & Development, a unit of US health care giant Johnson & Johnson (NYSE: JNJ) revealed…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

More ADA highlights, from Eli Lilly on dulaglutide, J&J on Invokana and GSK on albiglutide


Continued news from the 73rd Scientific Sessions of the American Diabetes Association being held in Chicago,…

albiglutideDiabetesdulaglutideEli LillyGlaxoSmithKlineInvokanaJohnson & JohnsonLY605541PharmaceuticalResearch

Johnson & Johnson in deal to buy Aragon Pharma for up to $1 billion


US health care giant Johnson & Johnson (NYSE: JNJ) has reached a definitive agreement to acquire Aragon…

Aragon PharmaceuticalsJohnson & JohnsonMergers & AcquisitionsOncologyPharmaceuticalSeragon Pharmaceuticals

Royalty bid for Elan could be withdrawn; J&J sells 25.4 million Elan shares


Ireland-based hostile takeover target Elan (NYSE: ELN) fell 5.2% to 9.29 euros on June 13, the most in…

ElanJohnson & JohnsonMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Second Genome in deal with Janssen on microbiome drug discovery in ulcerative colitis


Second Genome has entered into an agreement with Janssen Biotech, a subsidiary of US health care giant…

Gastro-intestinalsJanssenJohnson & JohnsonLicensingPharmaceuticalResearchSecond Genome

Bayer's Xarelto gains EU clearance for secondary prevention after ACS


German chemical and pharma group Bayer (BAYN: DE) says that its novel oral anticoagulant Xarelto (rivaroxaban)…

BayerCardio-vascularEuropeJohnson & JohnsonPharmaceuticalRegulationXarelto

Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth


At a meeting today with industry analysts, senior leaders from the Janssen pharmaceutical companies of…

FinancialJanssenJohnson & JohnsonPharmaceuticalRegulationResearch

US FDA approves Janssen's Simponi to treat ulcerative colitis


The US Food and Drug Administration late yesterday (May 15) approved a new use for Johnson & Johnson…

BiotechnologyGastro-intestinalsInflammatory diseasesJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi Injection

Six months post launch, US prescribing trends for Xtandi


At six months following launch of Xtandi (Astellas Pharma/Medivation's enzalutamide), surveyed urologists…

3MAstellas PharmaJevtanaJohnson & JohnsonMarkets & MarketingMedivationNorth AmericaOncologyPharmaceuticalSanofiXtandiZytiga

J&J's daratumumab gets "Breakthrough" status; GSK's trametinib delayed by FDA


The US Food and Drug Administration has granted "Breakthrough Therapy Designation" for health care giant…

daratumumabGenmabGlaxoSmithKlineJanssenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRegulationtrametinib

IQWiG says some men with metastatic prostate cancer can benefit from J&J's Zytiga


In an early benefit assessment pursuant to the German Act on the Reform of the Market for Medicinal Products…

EuropeJohnson & JohnsonOncologyPharmaceuticalPricingRegulationZytiga

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J


Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

Janssen files for European approval of hep C candidate simeprevir


Janssen-Cilag International, a European subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ),…

Anti-viralsBiotechnologyEuropeJanssen-CilagJohnson & JohnsonPharmaceuticalRegulationsimeprevir

Johnson & Johnson beats forecasts, despite 11% profit decline


Johnson & Johnson (NYSE: JNJ), the first of the US health care majors to report first-quarter 2013 financial…

FinancialJohnson & JohnsonPharmaceutical

Pharmacyclics and Janssen gain third FDA "Breakthrough" designation for ibrutinib; new Ph II data


Pharmacyclics (Nasdaq: PCYC) saw its shares gain 4.5% to $78.96 in early trading Monday, after it revealed…

ibrutinibJanssenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulationResearch

Janssen gains FDA approval of Invokana for type 2 diabetes; files simeprevir NDA


There were a couple of good news items for Johnson & Johnson (NYSE: JNJ) unit Janssen Pharmaceuticals…

Anti-viralsDiabetesInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevirTMC435

Xarelto and Eliquis set to displace current therapies in DVT/PE


Clinical data and the opinions of interviewed thought leaders indicate that there is little to distinguish…

BayerBristol-Myers SquibbCardio-vascularEliquisEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaPfizerPharmaceuticalXarelto

BioTrends views Xeljanz and Zytiga prescribing in USA


After around two months on the market, 37% of US rheumatologists have prescribed Pfizer's (NYSE: PFE)…

Anti-Arthritics/RheumaticsAstellas PharmaBiotechnologyJevtanaJohnson & JohnsonMedivationNorth AmericaOncologyPfizerPharmaceuticalSanofiXeljanzXtandiZytiga

101 to 125 of 254 results

Back to top